Donanemab + Placebo

Phase 3Recruiting

3 views this week 0 watching⚡ Active🧠Featured in Neuroscience Pipeline Watch

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer Disease

Conditions

Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

Trial Timeline

Oct 10, 2022 → Jul 1, 2028

NCT ID

NCT05508789

About Donanemab + Placebo

Donanemab + Placebo is a phase 3 stage product being developed by Eli Lilly for Alzheimer Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05508789. Target conditions include Alzheimer Disease, Dementia, Brain Diseases.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer Disease were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06911944	Approved	Recruiting	Aug 1, 2026	Dec 31, 2028	Down Syndrome (DS)
NCT05508789	Phase 3	Recruiting	Oct 10, 2022	Jul 1, 2028	Alzheimer Disease
NCT05533411	Phase 1	Completed	Sep 14, 2022	Jan 5, 2023	Healthy
NCT05026866	Phase 3	Active	Aug 27, 2021	Nov 1, 2027	Alzheimer Disease
NCT04437511	Phase 3	Active	Jun 19, 2020	Nov 1, 2028	Alzheimer Disease

Competing Products

20 competing products in Alzheimer Disease

See all competitors

Product	Company	Stage	Hype Score
[18F]NAV4694	Navidea Biopharmaceuticals	Phase 2	21
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	32
LY450139 + Placebo	Eli Lilly	Phase 3	40
Solanezumab + Placebo	Eli Lilly	Phase 3	32
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	35
Zagotenemab + Placebo	Eli Lilly	Phase 2	35
Donanemab + Placebo + LY3202626	Eli Lilly	Phase 2	35
GSK4527226	Alector	Phase 2	29
AL002 + Placebo	Alector	Phase 2	25
GSK4527226	Alector	Phase 2	32
AL002	Alector	Phase 2	17
Solanezumab + Placebo	Eli Lilly	Phase 3	32
donanemab	Eli Lilly	Phase 2	35
ATH-1017	LeonaBio	Phase 2/3	20
ATH-1017 + Placebo	LeonaBio	Phase 2/3	28
ATH-1017 + Placebo	LeonaBio	Phase 2	25
NDX-1017 + Placebo	LeonaBio	Phase 1	19
simufilam	Cassava Sciences	Phase 2	17
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125	Cassava Sciences	Phase 1	19
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tablet	Cassava Sciences	Phase 2	25